Search

Your search keyword '"Friedberg, Jonathan"' showing total 1,833 results
Start Over Author "Friedberg, Jonathan"
1,833 results on '"Friedberg, Jonathan"'

1. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Author

Smith, Mitchell R., Jegede, Opeyemi A., Martin, Peter, Till, Brian G., Parekh, Samir S., Yang, David T., Hsi, Eric D., Witzig, Thomas, Dave, Sandeep, Scott, David, Hanson, Curtis, Kostakoglu Shields, Lale, Abdel-Samad, Nizar, Casulo, Carla, Bartlett, Nancy L., Caimi, Paolo F., Al Baghdadi, Tareq, Blum, Kristie A., Romer, Mark D., Inwards, David J., Lerner, Rachel E., Wagner, Lynne I., Little, Richard F., Friedberg, Jonathan W., Leonard, John P., and Kahl, Brad S.

Published
2024
Full Text
View/download PDF

3. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

Author

Brem, Elizabeth A, Li, Hongli, Beaven, Anne W, Caimi, Paolo F, Cerchietti, Leandro, Alizadeh, Ash A, Olin, Rebecca, Henry, N Lynn, Dillon, Hildy, Little, Richard F, Laubach, Cara, LeBlanc, Michael, Friedberg, Jonathan W, and Smith, Sonali M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Hematology, Lymphoma, Clinical Trials and Supportive Activities, Aging, Rare Diseases, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Frailty, Humans, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Prospective Studies, Rituximab, DLBCL, Geriatric, Older, ctDNA, Oncology and carcinogenesis
Abstract

Diffuse large B cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy; however, cure is highly dependent on the ability to deliver intensive, anthracycline-based chemoimmunotherapy. Nearly one third of cases of DLBCL occur in patients over age 75 years, and advanced age is an important adverse feature in prognostic models. Despite this incidence in older patients, there is no clear accepted standard of care due to under-representation of this group in large randomized clinical trials. Furthermore, insufficient assessments of baseline frailty and prediction of toxicity hamper clinical decision-making. Here, we present an ongoing randomized study of R-miniCHOP chemoimmunotherapy with or without oral azacitidine (CC-486, Onureg) for patients age 75 and older with newly diagnosed DLBCL and associated aggressive lymphomas. The incorporation of an oral hypomethylating agent is based on increased tumor methylation as a biologic feature of older patients with DLBCL and a desire to minimize the injection burden for this population. This is the first randomized study in this population conducted in North America by the National Clinical Trials Network (NCTN) and will enroll up to 422 patients including 40 patients in a safety run-in phase. This study incorporates an objective assessment of baseline frailty (the FIL Tool) and a serial comprehensive geriatric assessment (CGA). Key correlative tests will include circulating tumor DNA (ctDNA) assays at pre-specified timepoints to explore if ctDNA quantity and methylation patterns correlate with response. S1918 has the potential to impact future trial design and to change the standard of care for patients 75 years and older with aggressive lymphoma given its randomized design, prospective incorporation of geriatric assessments, and exploration of ctDNA correlatives. Trial registration: The trial is registered with ClinicalTrial.gov Identifier NCT04799275.

Published
2022

9. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Author

Campo, Elias, Jaffe, Elaine S., Cook, James R., Quintanilla-Martinez, Leticia, Swerdlow, Steven H., Anderson, Kenneth C., Brousset, Pierre, Cerroni, Lorenzo, de Leval, Laurence, Dirnhofer, Stefan, Dogan, Ahmet, Feldman, Andrew L., Fend, Falko, Friedberg, Jonathan W., Gaulard, Philippe, Ghia, Paolo, Horwitz, Steven M., King, Rebecca L., Salles, Gilles, San-Miguel, Jesus, Seymour, John F., Treon, Steven P., Vose, Julie M., Zucca, Emanuele, Advani, Ranjana, Ansell, Stephen, Au, Wing-Yan, Barrionuevo, Carlos, Bergsagel, Leif, Chan, Wing C., Cohen, Jeffrey I., d'Amore, Francesco, Davies, Andrew, Falini, Brunangelo, Ghobrial, Irene M., Goodlad, John R., Gribben, John G., Hsi, Eric D., Kahl, Brad S., Kim, Won-Seog, Kumar, Shaji, LaCasce, Ann S., Laurent, Camille, Lenz, Georg, Leonard, John P., Link, Michael P., Lopez-Guillermo, Armando, Mateos, Maria Victoria, Macintyre, Elizabeth, Melnick, Ari M., Morschhauser, Franck, Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid, Pileri, Stefano A., Piris, Miguel, Pro, Barbara, Rajkumar, Vincent, Rosen, Steven T., Sander, Birgitta, Sehn, Laurie, Shipp, Margaret A., Smith, Sonali M., Staudt, Louis M., Thieblemont, Catherine, Tousseyn, Thomas, Wilson, Wyndham H., Yoshino, Tadashi, Zinzani, Pier-Luigi, Dreyling, Martin, Scott, David W., Winter, Jane N., and Zelenetz, Andrew D.

Published
2022
Full Text
View/download PDF

11. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

Author

Harkins, R. Andrew, Patel, Sharvil P., Lee, Michelle J., Switchenko, Jeffrey M., Ansell, Stephen M., Bartlett, Nancy L., Blum, Kristie A., Cashen, Amanda F., Casulo, Carla, Friedberg, Jonathan W., Johnston, Patrick B., Kahl, Brad S., Leonard, John P., Link, Brian K., Lossos, Izidore S., Martin, Peter, Maurer, Matt J., Mehta-Shah, Neha, Reagan, Patrick M., Westin, Jason R., Koff, Jean L., and Flowers, Christopher R.

Published
2022
Full Text
View/download PDF

12. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Author

Alderuccio, Juan Pablo, Arcaini, Luca, Watkins, Marcus P., Beaven, Anne W., Shouse, Geoffrey, Epperla, Narendranath, Spina, Michele, Stefanovic, Alexandra, Sandoval-Sus, Jose, Torka, Pallawi, Alpert, Ash B., Olszewski, Adam J., Kim, Seo-Hyun, Hess, Brian, Gaballa, Sameh, Ayyappan, Sabarish, Castillo, Jorge J., Argnani, Lisa, Voorhees, Timothy J., Saba, Raya, Chowdhury, Sayan Mullick, Vargas, Fernando, Reis, Isildinha M., Kwon, Deukwoo, Alexander, Jonathan S., Zhao, Wei, Edwards, Dali, Martin, Peter, Cencini, Emanuele, Kamdar, Manali, Link, Brian K., Logothetis, Constantine N., Herrera, Alex F., Friedberg, Jonathan W., Kahl, Brad S., Luminari, Stefano, Zinzani, Pier Luigi, and Lossos, Izidore S.

Published
2022
Full Text
View/download PDF

13. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

14. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Author

Neelapu, Sattva S, Locke, Frederick L, Bartlett, Nancy L, Lekakis, Lazaros J, Miklos, David B, Jacobson, Caron A, Braunschweig, Ira, Oluwole, Olalekan O, Siddiqi, Tanya, Lin, Yi, Timmerman, John M, Stiff, Patrick J, Friedberg, Jonathan W, Flinn, Ian W, Goy, Andre, Hill, Brian T, Smith, Mitchell R, Deol, Abhinav, Farooq, Umar, McSweeney, Peter, Munoz, Javier, Avivi, Irit, Castro, Januario E, Westin, Jason R, Chavez, Julio C, Ghobadi, Armin, Komanduri, Krishna V, Levy, Ronald, Jacobsen, Eric D, Witzig, Thomas E, Reagan, Patrick, Bot, Adrian, Rossi, John, Navale, Lynn, Jiang, Yizhou, Aycock, Jeff, Elias, Meg, Chang, David, Wiezorek, Jeff, and Go, William Y

Subjects
Rare Diseases, Orphan Drug, Lymphoma, Patient Safety, Clinical Research, Hematology, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Adult, Aged, Antigens, CD19, Biomarkers, Disease-Free Survival, Female, Humans, Immunotherapy, Adoptive, Interleukins, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Nervous System Diseases, Neutropenia, Receptors, Antigen, T-Cell, Survival Rate, T-Lymphocytes, Young Adult, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundIn a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.MethodsIn this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy. Patients received a target dose of 2×106 anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine. The primary end point was the rate of objective response (calculated as the combined rates of complete response and partial response). Secondary end points included overall survival, safety, and biomarker assessments.ResultsAmong the 111 patients who were enrolled, axi-cel was successfully manufactured for 110 (99%) and administered to 101 (91%). The objective response rate was 82%, and the complete response rate was 54%.With a median follow-up of 15.4 months, 42% of the patients continued to have a response, with 40% continuing to have a complete response. The overall rate of survival at 18 months was 52%. The most common adverse events of grade 3 or higher during treatment were neutropenia (in 78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 13% and 28% of the patients, respectively. Three of the patients died during treatment. Higher CAR T-cell levels in blood were associated with response.ConclusionsIn this multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events. (Funded by Kite Pharma and the Leukemia and Lymphoma Society Therapy Acceleration Program; ZUMA-1 ClinicalTrials.gov number, NCT02348216 .).

Published
2017

16. Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101

Author

Batchelor, Tracy T, primary, Giri, Sharmila, additional, Ruppert, Amy S., additional, Geyer, Susan, additional, Smith, Scott E, additional, Mohile, Nimish, additional, Swinnen, Lode J, additional, Friedberg, Jonathan W., additional, Kahl, Brad S., additional, Bartlett, Nancy L., additional, Hsi, Eric D., additional, Cheson, Bruce David, additional, Wagner-Johnston, Nina D, additional, Nayak, Lakshmi, additional, Leonard, John P., additional, and Rubenstein, James Louis, additional

Published
2024
Full Text
View/download PDF

17. Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma

Author

Upshaw, Jenica N., primary, Nelson, Jason, additional, Sweigart, Benjamin, additional, Rodday, Angie Mae, additional, Kumar, Anita J., additional, Konstam, Marvin A., additional, Wong, John B., additional, Ky, Bonnie, additional, Karmiy, Samuel, additional, Friedberg, Jonathan W., additional, Evens, Andrew M., additional, Kent, David M., additional, and Parsons, Susan K., additional

Published
2024
Full Text
View/download PDF

20. Clinical Evaluation

Author

Armitage, James O., Friedberg, Jonathan W., Dreyling, Martin, Series Editor, Engert, Andreas, editor, and Younes, Anas, editor

Published
2020
Full Text
View/download PDF

22. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

24. High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.

Author

Peppone, Luke J., Kleckner, Amber S., Fung, Chunkit, Puzas, J. Edward, Reschke, Jennifer E., Culakova, Eva, Inglis, Julia, Kamen, Charles, Friedberg, Jonathan W., Janelsins, Michelle, Mustian, Karen, Heckler, Charles E., and Mohile, Supriya

Subjects
FEMUR neck, ANDROGEN deprivation therapy, PROSTATE cancer patients, BONE density, DUAL-energy X-ray absorptiometry, BONE growth, TERIPARATIDE, ANDROGEN receptors
Abstract

Background: Androgen deprivation therapy (ADT) inhibits prostate cancer growth. However, ADT causes loss of bone mineral density (BMD) and an increase in fracture risk; effective interventions for ADT‐induced bone loss are limited. Methods: A phase 2 randomized controlled trial investigated the feasibility, safety, and preliminary efficacy of high‐dose weekly vitamin D (HDVD, 50,000 IU/week) versus placebo for 24 weeks in patients with prostate cancer receiving ADT, with all subjects receiving 600 IU/day vitamin D and 1000 mg/day calcium. Participants were ≥60 years (mean years, 67.7), had a serum 25‐hydroxyvitamin D level <32 ng/mL, and initiated ADT within the previous 6 months. At baseline and after intervention, dual‐energy x‐ray absorptiometry was used to assess BMD, and levels of bone cell, bone formation, and resorption were measured. Results: The HDVD group (N = 29) lost 1.5% BMD at the total hip vs. 4.1% for the low‐dose group (N = 30; p =.03) and 1.7% BMD at the femoral neck vs. 4.4% in the low‐dose group (p =.06). Stratified analyses showed that, for those with baseline 25‐hydroxyvitamin D level <27 ng/mL, the HDVD group lost 2.3% BMD at the total hip vs 7.1% for the low‐dose group (p <.01). Those in the HDVD arm showed significant changes in parathyroid hormone (p <.01), osteoprotegerin (p < 0.01), N‐terminal telopeptide of type 1 collagen (p < 0.01) and C‐terminal telopeptide of type 1 collagen (p < 0.01). No difference in adverse events or toxicity was noted between the groups. Conclusions: HDVD supplementation significantly reduced hip and femoral neck BMD loss, especially for patients with low baseline serum 25‐hydroxyvitamin D levels, although demonstrating safety and feasibility in prostate cancer patients on ADT. Patients with prostate cancer on androgen deprivation therapy often suffer rapid bone loss during the initiation of treatment. Supplementation with high‐dose vitamin D (50,000 IU/week plus 800 IU/day) significantly and safely decreased the amount of bone loss compared with vitamin D supplementation using the recommended daily allowance (800 IU/day). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

Author

Lo, Andrea C., primary, Liu, Amy, additional, Liu, Qi, additional, Yasui, Yutaka, additional, Castellino, Sharon M., additional, Kelly, Kara M., additional, Hererra, Alex F., additional, Friedberg, Jonathan W., additional, Friedman, Debra L., additional, Schwartz, Cindy L., additional, Pei, Qinglin, additional, Kessel, Sandy, additional, Bergeron-Gravel, Samuel, additional, Dama, Hitesh, additional, Roberts, Kenneth, additional, Constine, Louis S., additional, and Hodgson, David C., additional

Published
2024
Full Text
View/download PDF

26. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Author

Boyiadzis, Michael, Bishop, Michael, Abonour, Rafat, Anderson, Kenneth, Ansell, Stephen, Avigan, David, Barbarotta, Lisa, Barrett, Austin, Van Besien, Koen, Bergsagel, P, Borrello, Ivan, Brody, Joshua, Brufsky, Jill, Cairo, Mitchell, Chari, Ajai, Cohen, Adam, Cortes, Jorge, Forman, Stephen, Friedberg, Jonathan, Fuchs, Ephraim, Gore, Steven, Jagannath, Sundar, Kahl, Brad, Kline, Justin, Kochenderfer, James, Kwak, Larry, Levy, Ronald, de Lima, Marcos, Litzow, Mark, Mahindra, Anuj, Miller, Jeffrey, Munshi, Nikhil, Orlowski, Robert, Pagel, John, Porter, David, Russell, Stephen, Schwartz, Karl, Shipp, Margaret, Siegel, David, Stone, Richard, Tallman, Martin, Timmerman, John, Van Rhee, Frits, Waller, Edmund, Welsh, Ann, Werner, Michael, Wiernik, Peter, and Dhodapkar, Madhav

Subjects
Acute leukemia, Cancer immunotherapy, Hematologic malignancies, Immunotherapy, Lymphoma, Multiple myeloma
Abstract

Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicines clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.

Published
2016

27. T-Cell–Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features

Author

El Hussein, Siba, primary, Fang, Hong, additional, Jelloul, Fatima Zahra, additional, Wang, Wei, additional, Loghavi, Sanam, additional, Miranda, Roberto N., additional, Friedberg, Jonathan W., additional, Burack, W. Richard, additional, Evans, Andrew G., additional, Xu, Jie, additional, and Medeiros, L. Jeffrey, additional

Published
2023
Full Text
View/download PDF

29. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy

Author

Friedberg, Jonathan W., primary, Bordoni, Rodolfo Eduardo, additional, Patel-Donnelly, Dipti, additional, Larson, Timothy, additional, Goldschmidt, Jerome, additional, Boccia, Ralph, additional, Cline, Vivian J. M., additional, Mamidipalli, Adrija, additional, Liu, Jingmin, additional, Akyol, Alev, additional, and Yasenchak, Christopher, additional

Published
2023
Full Text
View/download PDF

30. 1423 Novel immunotherapy based on commensal-derived peptides to drive an effective CD8 T Cell response against selected tumor-associated antigens (TAAs)

Author

Talpin, Alice, primary, Kervevan, Jerome, additional, Aubergeon, Lucie, additional, Maia, Ana, additional, Blanc, Tifanny Mersceman, additional, Bachrouche, Diana, additional, Ventujol, Chloé, additional, Bernard, Léa, additional, Manteau, Amandine, additional, Gouttefangeas, Cecile, additional, Villasboas, Jose, additional, Pinto, Antonello, additional, Bosch, Francesc, additional, García-Sanz, Ramon, additional, Garcia, Carlos Grande, additional, Smith, Stephen D, additional, Arcaini, Luca, additional, Merryman, Reid, additional, Friedberg, Jonathan W, additional, Ansell, Stephen, additional, Armand, Philippe, additional, Zinzani, Pier, additional, Bonny, Christophe, additional, Chene, Laurent, additional, and Magalhaes, Joao Gamelas, additional

Published
2023
Full Text
View/download PDF

31. Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

Author

Diefenbach, Catherine S, Li, Hailun, Hong, Fangxin, Gordon, Leo I, Fisher, Richard I, Bartlett, Nancy L, Crump, Michael, Gascoyne, Randy D, Wagner, Henry, Stiff, Patrick J, Cheson, Bruce D, Stewart, Douglas A, Kahl, Brad S, Friedberg, Jonathan W, Blum, Kristie A, Habermann, Thomas M, Tuscano, Joseph M, Hoppe, Richard T, Horning, Sandra J, and Advani, Ranjana H

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Patient Safety, Hematology, Clinical Research, Lymphoma, Cancer, Rare Diseases, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Area Under Curve, Bleomycin, Clinical Trials, Phase III as Topic, Dacarbazine, Disease-Free Survival, Doxorubicin, Etoposide, Hodgkin Disease, Humans, Kaplan-Meier Estimate, Mechlorethamine, Multicenter Studies as Topic, Prednisone, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Sample Size, Severity of Illness Index, Survival Analysis, Vinblastine, Vincristine, ABVD, Hodgkin lymphoma, International Prognostic Score, Stanford V, prognostic score, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The International Prognostic Score (IPS-7) is the most commonly used risk stratification tool for advanced Hodgkin lymphoma (HL), however recent studies suggest the IPS-7 is less discriminating due to improved outcomes with contemporary therapy. We evaluated the seven variables for IPS-7 recorded at study entry for 854 patients enrolled on Eastern Cooperative Oncology Group 2496 trial. Univariate and multivariate Cox models were used to assess their prognostic ability for freedom from progression (FFP) and overall survival (OS). The IPS-7 remained prognostic however its prognostic range has narrowed. On multivariate analysis, two factors (age, stage) remained significant for FFP and three factors (age, stage, haemoglobin level) for OS. An alternative prognostic index, the IPS-3, was constructed using age, stage and haemoglobin level, which provided four distinct risk groups [FFP (P = 0·0001) and OS (P

Published
2015

32. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial

Author

Advani, Ranjana H, Hong, Fangxin, Fisher, Richard I, Bartlett, Nancy L, Robinson, K Sue, Gascoyne, Randy D, Wagner, Henry, Stiff, Patrick J, Cheson, Bruce D, Stewart, Douglas A, Gordon, Leo I, Kahl, Brad S, Friedberg, Jonathan W, Blum, Kristie A, Habermann, Thomas M, Tuscano, Joseph M, Hoppe, Richard T, and Horning, Sandra J

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Hematology, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Chemotherapy, Adjuvant, Cyclophosphamide, Dacarbazine, Disease-Free Survival, Doxorubicin, Etoposide, Female, Hodgkin Disease, Humans, Kaplan-Meier Estimate, Male, Mechlorethamine, Mediastinal Neoplasms, Middle Aged, Neoplasm Staging, North America, Prednisone, Procarbazine, Radiotherapy, Adjuvant, Risk Factors, Treatment Outcome, Vinblastine, Vincristine, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe phase III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma) compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechlorethamine, doxorubicin, vincristine, bleomycin, vinblastine, etoposide, and prednisone (Stanford V). We report results of a planned subgroup analysis in patients with stage I or II bulky mediastinal Hodgkin lymphoma (HL).Patients and methodsPatients were randomly assigned to six to eight cycles of ABVD every 28 days or Stanford V once per week for 12 weeks. Two to 3 weeks after completion of chemotherapy, all patients received 36 Gy of modified involved field radiotherapy (IFRT) to the mediastinum, hila, and supraclavicular regions. Patients on the Stanford V arm received IFRT to additional sites ≥ 5 cm at diagnosis. Primary end points were failure-free survival (FFS) and overall survival (OS).ResultsOf 794 eligible patients, 264 had stage I or II bulky disease, 135 received ABVD, and 129 received Stanford V. Patient characteristics were matched. The overall response rate was 83% with ABVD and 88% with Stanford V. At a median follow-up of 6.5 years, the study excluded a difference of more than 21% in 5-year FFS and more than 16% in 5-year OS between ABVD and Stanford V (5-year FFS: 85% v 79%; HR, 0.68; 95% CI, 0.37 to 1.25; P = .22; 5-year OS: 96% v 92%; HR, 0.49; 95% CI, 0.16 to 1.47; P = .19). In-field relapses occurred in < 10% of the patients in each arm.ConclusionFor patients with stage I or II bulky mediastinal HL, no substantial statistically significant differences were detected between the two regimens, although power was limited. To the best of our knowledge, this is the first prospective trial reporting outcomes specific to this subgroup, and it sets a benchmark for comparison of ongoing and future studies.

Published
2015

37. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Author

Dunleavy, Kieron, Fanale, Michelle A, Abramson, Jeremy S, Noy, Ariela, Caimi, Paolo Fabrizio, Pittaluga, Stefania, Parekh, Samir, Lacasce, Ann, Hayslip, John W, Jagadeesh, Deepa, Nagpal, Sunil, Lechowicz, Mary Jo, Gaur, Rakesh, Lucas, Andrea, Melani, Christopher, Roschewski, Mark, Steinberg, Seth M, Jaffe, Elaine S, Kahl, Brad, Friedberg, Jonathan W, Little, Richard F, Bartlett, Nancy L, and Wilson, Wyndham H

Published
2018
Full Text
View/download PDF

40. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Author

Lakhotia, Rahul, primary, Dunleavy, Kieron, additional, Abramson, Jeremy S., additional, Link, Brian K., additional, Powell, Bayard L., additional, Melani, Christopher, additional, Lucas, Andrea N., additional, Steinberg, Seth M., additional, Friedberg, Jonathan W., additional, Kahl, Brad S., additional, Little, Richard F., additional, Bartlett, Nancy L., additional, Noy, Ariela, additional, Wilson, Wyndham H., additional, and Roschewski, Mark, additional

Published
2023
Full Text
View/download PDF

44. ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Author

Flowers, Christopher, Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H., Friedberg, Jonathan W., Trněný, Marek, Sharman, Jeff P., Herbaux, Charles, Burke, John M., Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan Miguel, Cheung, Matthew C., Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, and Salles, Gilles

Published
2022
Full Text
View/download PDF

45. HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

Author

Straus, David, Radford, John, Connors, Joseph, Kim, Won Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan, Advani, Ranjana, Hutchings, Martin, Evens, Andrew, Smolewski, Piotr, Savage, Kerry, Bartlett, Nancy, Eom, Hyeon-Seok, Abramson, Jeremy, Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, and Ansell, Stephen

Published
2022
Full Text
View/download PDF

49. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis

Author

Casulo, Carla, Friedberg, Jonathan W., Ahn, Kwang W., Flowers, Christopher, DiGilio, Alyssa, Smith, Sonali M., Ahmed, Sairah, Inwards, David, Aljurf, Mahmoud, Chen, Andy I., Choe, Hannah, Cohen, Jonathon, Copelan, Edward, Farooq, Umar, Fenske, Timothy S., Freytes, Cesar, Gaballa, Sameh, Ganguly, Siddhartha, Jethava, Yogesh, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard, Lazaryan, Aleksandr, Olsson, Richard F., Rezvani, Andrew R., Rizzieri, David, Seo, Sachiko, Shah, Gunjan L., Shah, Nina, Solh, Melham, Sureda, Anna, William, Basem, Cumpston, Aaron, Zelenetz, Andrew D., Link, Brian K., and Hamadani, Mehdi

Published
2018
Full Text
View/download PDF

50. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703)

Author

Smith, Eileen P., Li, Hongli, Friedberg, Jonathan W., Constine, Louis S., Rimsza, Lisa M., Cook, James R., Laport, Ginna G., Popplewell, Leslie L., Holmberg, Leona A., Smith, Sonali M., LeBlanc, Michael, Forman, Stephen J., Fisher, Richard I., and Stiff, Patrick J.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results